Heparanase: A Dynamic Promoter of Myeloma Progression.
Heparanase: A Dynamic Promoter of Myeloma Progression.
复制标题
DOI：
10.1007/978-3-030-34521-1_12
复制
发表时间：
2020
影响因子：
--
通讯作者：
Sanderson RD
中科院分区：
文献类型：
--
作者：
Purushothaman A;Sanderson RD
摘要仅在网上发布。如果您在提交稿件时没有包括在线版本的简短摘要，则该章节的第一段或前10行将显示在此处。如果可能的话，请给我们提供一个信息摘要。多年来一直推测乙酰肝素酶在癌症的进展中起重要作用，这主要是由于发现其在正常组织中的表达较弱或不存在，但通常随着肿瘤变得更具侵袭性，乙酰肝素酶表达增加。然而，直到最近十年左右，我们才开始了解乙酰肝素酶在癌症中扮演的邪恶角色背后的分子机制。在这篇综述中，我们描述了乙酰肝素酶在促进多发性骨髓瘤的生长、血管生成和转移中的许多功能，多发性骨髓瘤是一种毁灭性的癌症，主要定位于骨髓内，并在整个骨骼系统中扩散，吞噬骨骼，最终导致几乎所有诊断患有这种疾病的患者死亡。我们还探讨了乙酰肝素酶如何引发外泌体生物合成以及乙酰肝素酶如何增强骨髓瘤肿瘤化疗耐药性的最新发现。这些由乙酰肝素酶驱动的多种肿瘤促进途径的发现将该酶确定为应用新型乙酰肝素酶抑制剂的治疗的理想靶点，该抑制剂最近在骨髓瘤患者的I期试验中进行了测试。
The abstract is published online only. If you did not include a short abstract for the online version when you submitted the manuscript, the first paragraph or the first 10 lines of the chapter will be displayed here. If possible, please provide us with an informative abstract. It has been speculated for many years that heparanase plays an important role in the progression of cancer due largely to the finding that its expression is weak or absent in normal tissues but generally as tumors become more aggressive heparanase expression increases. However, it is only in the last decade or so that we have begun to understand the molecular mechanism behind the sinister role that heparanase plays in cancer. In this review, we describe the many functions of heparanase in promoting the growth, angiogenesis and metastasis of multiple myeloma, a devastating cancer that localizes predominantly within the bone marrow and spreads throughout the skeletal system devouring bone and ultimately leading to death of almost all patients diagnosed with this disease. We also explore recent discoveries related to how heparanase primes exosome biogenesis and how heparanase enhances myeloma tumor chemoresistance. Discovery of these multiple tumor-promoting pathways that are driven by heparanase identified the enzyme as an ideal target for therapy of applying a novel heparanase inhibitor recently tested in a Phase I trial in myeloma patients.
登录
查看更多内容
影响因子：
4
作者：
Buczek-Thomas, Jo Ann;Hsia, Edward;Rich, Celeste B.;Foster, Judith A.;Nugent, Matthew A.
通讯作者：
Nugent, Matthew A.
影响因子：
20.3
作者：
Mahtouk, Karene;Hose, Dirk;Klein, Bernard
通讯作者：
Klein, Bernard
影响因子：
2.1
作者：
David, Guido;Zimmermann, Pascale
通讯作者：
Zimmermann, Pascale
影响因子：
3.7
作者：
Brockstedt, U;Dobra, K;Hjerpe, A
通讯作者：
Hjerpe, A
影响因子：
--
作者：
Couchman, John R;Multhaupt, Hinke;Sanderson, Ralph D
通讯作者：
Sanderson, Ralph D